Finland-based DelSiTech has signed a world-wide, exclusive license agreement with Innovare R&D, a Mexico-based pharma company, it was reported yesterday.
The contract has been signed for the use of the former's Silica Matrix drug delivery platform in the development and commercialisation of a long acting HIV therapy.
According to the terms of the agreement, Innovare will use DelSiTech's technology on its peptide membrane fusion inhibitor, targeting the envelope protein of human immunodeficiency virus-1. DelSiTech is entitled to receive an upfront payment, milestone payments and royalties on development, commercialisation and sales of the Silica Matrix formulated T1144 drug product. Financial details of the deal were not revealed.
Bruker demonstrates advancements in 4D-Proteomics at US HUPO
Mitem Pharma acquires Flisint rights from Sanofi to address rare infectious disease
Audientes partners with Audivista to expand hearing solutions in Middle East and North Africa
Benuvia Operations signs licensing deal with Avernus Pharma
Benuvia Operations signs licensing and supply agreements with Medra Brasil Medicamentos
Castle Biosciences to present data on Melanoma tests at ASDP Annual Meeting
Alchemy partners with PatchRx to improve HIV medication adherence
Gilead expands global access to lenacapavir for HIV prevention